Dr. Marasco is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Jfb 824
Boston, MA 02115Phone+1 617-632-2153
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1988 - 1990
- University of MichiganResidency, Internal Medicine, 1986 - 1988
- University of Michigan Medical SchoolClass of 1986
Certifications & Licensure
- MA State Medical License 1988 - 2025
- MI State Medical License 1987 - 1991
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Publications & Presentations
PubMed
- 1 citationsAnti-CD99 Antibody Therapy Triggers Macrophage-Dependent Ewing Cell Death In Vitro and Myeloid Cell Recruitment In Vivo.Allison F O'Neill, Evelyn M Nguyen, Evelyn D Maldonado, Matthew R Chang, Jiusong Sun
Antibodies. 2024-03-18 - 4 citationsAffinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.Yufei Wang, Alicia Buck, Brandon Piel, Luann Zerefa, Nithyassree Murugan
Molecular Cancer. 2024-03-16 - 6 citationsImmune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model.Yufei Wang, Jae-Won Cho, Gabriella Kastrunes, Alicia Buck, Cecile Razimbaud
Iscience. 2024-02-16
Journal Articles
- Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance Against a Broadly Neutralizing Hemagglutinin Stem AntibodyRobert W Finberg, Wayne A Marasco, Jennifer P Wang, mBio
Press Mentions
- FDA Advisers Vote to Include an Omicron-Specific Component for a Coronavirus Booster in the USJune 28th, 2022
- Pfizer, Moderna, Novavax: FDA Experts Vote 19-2 to Include Omicron Shot in Covid BoostersJune 28th, 2022
- 13 Notable Pioneers in the Field of MedicineJanuary 2nd, 2021
- Join now to see all
Grant Support
- Study Of Broadly Neutralizing Antibody Generation To HIV Gp140 In Humanized MiceNational Institute Of Allergy And Infectious Diseases2010–2011
- Broad Spectrum Neutralizing Human Abs To SARS And Related CoronavirusesNational Institute Of Allergy And Infectious Diseases2010–2011
- Spore Core 1: Administrative, Evaluation And PlanningNational Cancer Institute2009–2011
- Human MAB Cocktails To Prevent &Treat H5N1 Avian InfluenzaNational Institute Of Allergy And Infectious Diseases2007–2011
- Anti-Hiv-1 TAT Human SFV Intrabody Gene Therapy Against SHIV In Rhesus MacaquesNational Center For Research Resources2003–2011
- Novel Vaginal Microbicides Based On Stable Aav-Neutralizing Antibody Gene TransfeNational Institute Of Allergy And Infectious Diseases2010
- Novel Vaginal Microbicides Based On Stable Aav-Neutralizing Antibody Gene TransfeNational Institute Of Allergy And Infectious Diseases2008–2009
- Generation Of A Therapeutic Antibody Directed Against CCR4 For Patients WithNational Cancer Institute2008
- Studies Of CCR5 Conformational Heterogeneity &Hiv EntryNational Institute Of Allergy And Infectious Diseases2004–2008
- Human Antibodies And Targeted Vaccines Against SARS-COVNational Institute Of Allergy And Infectious Diseases2004–2008
- Role Of SHP-1 Deregulation In HTLV-1 LeukemogenesisNational Cancer Institute2004–2008
- Human Anti-Macaque CCR5 Mabs For Passive ImmunotherapyNational Institute Of Allergy And Infectious Diseases2003–2007
- Genetic Retargeted Human T-Cells For RCC ImmunotherapyNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
- Anti-Hiv-1 TAT Human SFV Intrabody Gene TherapyNational Center For Research Resources2004
- Targeting Human Cyclin T1 To Inhibit HIV-1 ReplicationNational Institute Of Allergy And Infectious Diseases2003–2004
- Global Analysis Of Transcriptional Deregulation By HIV-1National Institute Of Allergy And Infectious Diseases2002–2003
- Role Of Grb3-3 In T-Cell Activation &Hiv-1 ReplicationNational Institute Of Allergy And Infectious Diseases2001–2003
- Intraceullular Anti-Tat Antibodies For AIDS Gene TherapyNational Institute Of Allergy And Infectious Diseases2000–2002
- Gene Therapy By Phenotypic Knockout Of HIV CoreceptorsNational Institute Of Allergy And Infectious Diseases1998–2002
- Human Antitat Intrabody Gene Therapy Against SHIVNational Center For Research Resources1999–2001
- Intracellular Antitat Antibodies For AIDS Gene TherapyNational Institute Of Allergy And Infectious Diseases1995–1999
- Gene Therapy Aids--A Recombinant Antibody-Based StrategyNational Institute Of Allergy And Infectious Diseases1994–1997
- Repertoire Cloning Of Anti-Hiv-1 Gp120/Gp41 AntibodiesNational Institute Of Allergy And Infectious Diseases1993–1997
- Mechanism Of Action Of The TAT Product Of HIV-1National Institute Of Allergy And Infectious Diseases1993
- Cd23--Autocrine Growth Factor And ReceptorNational Cancer Institute1989–1991
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: